On Tuesday, TD Cowen maintained a Hold rating on shares of Zimmer Biomet (NYSE:ZBH), with a consistent price target of $143.00. The firm's stance comes ahead of the medical device company's Investor Day, scheduled for May 29.
The decision by TD Cowen to keep Zimmer Biomet at a Hold rating follows a conversation with an orthopedic surgeon familiar with the company's latest product offerings, including Persona IQ and OsseoTi cementless. These innovations are believed to have the potential to drive revenue growth for Zimmer Biomet.
TD Cowen anticipates that Zimmer Biomet will provide a more detailed outlook on the contributions of these new products during the upcoming Investor Day. The firm's confidence in the future revenue growth from Persona IQ and OsseoTi cementless has been bolstered by insights from the medical professional who has hands-on experience with these devices.
As Zimmer Biomet prepares to share more information with investors and analysts, the market's focus will be on the company's ability to leverage its new products for financial growth. The current price target reflects TD Cowen's assessment of the company's value based on available information.
Investors and stakeholders in Zimmer Biomet will be looking to the Investor Day presentation for clarity on the company's strategic plans and the expected impact of its latest pipeline offerings on its financial performance. The event is poised to offer a comprehensive update on Zimmer Biomet's progress and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.